Monoclonal antibodies are prescription medications, so getting them starts with a doctor who determines whether one is appropriate for your condition. These lab-made proteins are now used to treat a wide range of diseases, from cancer and autoimmune conditions to migraines and Alzheimer’s. If you’re specifically looking for COVID-19 monoclonal antibodies, availability has changed dramatically: most have been pulled from distribution, with only limited options remaining for certain immunocompromised patients.
What Monoclonal Antibodies Treat Today
Monoclonal antibodies are designed to target specific proteins in the body, and dozens are now FDA-approved for different conditions. The major categories include cancer therapy, where they help the immune system attack tumor cells or deliver chemotherapy directly to cancer sites. They’re also widely used for autoimmune diseases like rheumatoid arthritis, psoriasis, and lupus, where they dial down an overactive immune response.
Beyond those two big categories, monoclonal antibodies treat migraine prevention, macular degeneration (a cause of vision loss), high cholesterol that doesn’t respond to standard medications, asthma, osteoporosis, and early Alzheimer’s disease. More than 20 biosimilar versions of older monoclonal antibodies have also been approved, which can lower costs for patients with autoimmune or cancer diagnoses. The specific antibody you’d receive depends entirely on your condition, so the path to getting one varies.
The General Process for Non-COVID Conditions
For most conditions, the process follows a standard prescription pathway. Your doctor, whether a primary care physician or a specialist like an oncologist or rheumatologist, evaluates your diagnosis and determines that a monoclonal antibody is the right treatment. Many of these drugs are reserved for cases where first-line treatments haven’t worked well enough, or where the condition is severe enough to justify the cost and complexity of infusion therapy.
Once prescribed, your doctor’s office coordinates with an infusion center, hospital outpatient department, or specialty pharmacy. Some monoclonal antibodies come as self-injectable pens or prefilled syringes you can use at home, similar to insulin. Migraine prevention antibodies, for example, are typically self-administered as a monthly injection. Others require intravenous infusion in a clinical setting, which is common for cancer and autoimmune treatments.
For Alzheimer’s-specific monoclonal antibodies like lecanemab, Medicare Part B covers the treatment but requires your healthcare provider to collect data on how well the drug works for you as part of a qualifying study or registry. This extra step exists because these drugs are relatively new, and coverage is tied to ongoing evidence collection.
Where Infusions Are Administered
If your monoclonal antibody requires an IV infusion, you’ll typically receive it at a hospital outpatient center, a standalone infusion center, or sometimes a doctor’s office equipped for infusions. Each session involves sitting in a chair while the medication drips through an IV line, followed by a monitoring period of about an hour afterward. The infusion itself can take anywhere from 30 minutes to several hours depending on the specific drug.
Home infusion is an option for some patients, particularly those who are homebound, live in rural areas, or reside in long-term care facilities. Home infusion requires a trained nurse to administer the drug and monitor you during and after the session. Your doctor and insurance company would need to approve this arrangement, and not all monoclonal antibodies are available through home infusion services.
Side Effects and Monitoring
Side effects from monoclonal antibody infusions are uncommon, occurring in fewer than 1 in 100 patients. When they do happen, they usually show up within the first hour after the infusion. The most notable risk is an allergic reaction, which can include shortness of breath, rash, itching, or dizziness. This is why you’re monitored for roughly an hour after each session before being sent home.
Some monoclonal antibodies carry specific risks tied to what they target. Immunosuppressive antibodies used for autoimmune diseases can increase your susceptibility to infections. Cancer immunotherapy antibodies can sometimes cause the immune system to attack healthy tissue. Your prescribing doctor will explain the risks specific to your medication and schedule regular check-ins or lab work to catch problems early.
What COVID-19 Monoclonal Antibodies Look Like Now
If you’re searching because you have COVID-19 and want monoclonal antibody treatment, the landscape is very different from 2021 and 2022. The federal government halted distribution of all infusion-based COVID therapeutics, and the National Infusion Center Association has discontinued its COVID-19 treatment site locator tool. Most of the monoclonal antibodies that were authorized during the pandemic lost effectiveness against newer variants and had their emergency use authorizations revoked.
One narrow exception remains: pemivibart (brand name Pemgarda), which has emergency use authorization for pre-exposure prevention of COVID-19, not treatment of an active infection. It’s available only to adults and adolescents 12 and older who weigh at least 40 kg, are not currently infected with COVID-19, have moderate-to-severe immune compromise from a medical condition or immunosuppressive treatment, and are unlikely to mount an adequate response to vaccination. If you fit that profile, your immunologist or prescribing specialist can determine eligibility and arrange administration.
For most people who currently have COVID-19, the primary outpatient treatment option is antiviral medication rather than monoclonal antibodies. Your doctor can prescribe antivirals if you’re at high risk for severe disease.
Cost and Insurance Coverage
Monoclonal antibodies are among the most expensive medications available, with list prices that can range from a few thousand to tens of thousands of dollars per dose depending on the drug and condition. Insurance coverage varies significantly by the specific antibody, your diagnosis, and your plan.
Medicare Part B covers monoclonal antibodies administered in a clinical setting, with patients paying 20% of the Medicare-approved amount after meeting the Part B deductible. Scans and tests required before or during treatment can add to out-of-pocket costs. If a particular antibody isn’t covered under Part B, it may be available through a Part D prescription drug plan instead. Private insurance generally covers FDA-approved monoclonal antibodies but often requires prior authorization, meaning your doctor must submit documentation proving the treatment is medically necessary before the insurer agrees to pay.
Many manufacturers offer patient assistance programs or copay cards that can significantly reduce costs. If you’re facing a high price tag, ask your doctor’s office or the drug manufacturer about financial assistance options before starting treatment. Specialty pharmacies that handle these medications often have staff dedicated to helping patients navigate insurance approvals and find cost relief.